Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes of Helicobacter pylori isolates influence the outcome of triple therapy

R. Ram M, X. Teh, T. Rajakumar, KL. Goh, AHR. Leow, BH. Poh, V. Mariappan, EM. Shankar, MF. Loke, J. Vadivelu,

. 2019 ; 74 (1) : 11-16. [pub] 20190101

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Objectives: Eradication of Helicobacter pylori is influenced by susceptibility to antimicrobial agents, elevated bacterial load and degree of acid inhibition, which can be affected by genotypes of drug-metabolizing enzymes [cytochrome P450 (CYP) 2C19 polymorphism]. Theoretically, the choice and dose of proton pump inhibitor may also influence the suppression of H. pylori infection. The CYP2C19 genotype has recently been found to have an impact on peptic ulcer healing, H. pylori eradication and therapeutic efficacy of proton pump inhibitors. Methods: Here, we investigated the impact of the CYP2C19 genotype polymorphism and the success of triple therapy (fluoroquinolones/metronidazole/clarithromycin) on antibiotic-resistant strains in eradicating H. pylori in human subjects with non-ulcer dyspepsia (NUD), in human subjects with peptic ulcer disease (PUD) and in asymptomatic human subjects (positive and negative for H. pylori infection). Results: Based on the CYP2C19 genotypes, determined by Droplet Digital PCR (ddPCR) analysis, we found 11.2%, 62.5% and 26.3% corresponding to rapid metabolizers, intermediate metabolizers and poor metabolizers, respectively. However, we did not find any significant effect for homozygous ABCB1 or CYP2C19*2 and CYP2C19*3 alleles. We detected several participants heterozygous for both ABCB1 and CYP2C19*2, CYP2C19*3 and CYP2C19*17 loci. The participants heterozygous for both ABCB1 and CYP2C19*2 and *3 loci should be defined as intermediate and poor metabolizers according to the haplotype analysis in the NUD, PUD and asymptomatic subjects. Conclusions: Consequently, fluoroquinolones/metronidazole/clarithromycin-based triple therapies can be used to eradicate H. pylori infection, if one does not know the CYP2C19 genotype of the patient.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006737
003      
CZ-PrNML
005      
20200522110604.0
007      
ta
008      
200511s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/jac/dky401 $2 doi
035    __
$a (PubMed)30403784
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Ram M, Ravishankar $u Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. Department of Molecular Biology and Genetics, Faculty of Science, University of South Bohemia, Branišovská 31, České Budějovice (Budweis), Czech Republic.
245    10
$a Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes of Helicobacter pylori isolates influence the outcome of triple therapy / $c R. Ram M, X. Teh, T. Rajakumar, KL. Goh, AHR. Leow, BH. Poh, V. Mariappan, EM. Shankar, MF. Loke, J. Vadivelu,
520    9_
$a Objectives: Eradication of Helicobacter pylori is influenced by susceptibility to antimicrobial agents, elevated bacterial load and degree of acid inhibition, which can be affected by genotypes of drug-metabolizing enzymes [cytochrome P450 (CYP) 2C19 polymorphism]. Theoretically, the choice and dose of proton pump inhibitor may also influence the suppression of H. pylori infection. The CYP2C19 genotype has recently been found to have an impact on peptic ulcer healing, H. pylori eradication and therapeutic efficacy of proton pump inhibitors. Methods: Here, we investigated the impact of the CYP2C19 genotype polymorphism and the success of triple therapy (fluoroquinolones/metronidazole/clarithromycin) on antibiotic-resistant strains in eradicating H. pylori in human subjects with non-ulcer dyspepsia (NUD), in human subjects with peptic ulcer disease (PUD) and in asymptomatic human subjects (positive and negative for H. pylori infection). Results: Based on the CYP2C19 genotypes, determined by Droplet Digital PCR (ddPCR) analysis, we found 11.2%, 62.5% and 26.3% corresponding to rapid metabolizers, intermediate metabolizers and poor metabolizers, respectively. However, we did not find any significant effect for homozygous ABCB1 or CYP2C19*2 and CYP2C19*3 alleles. We detected several participants heterozygous for both ABCB1 and CYP2C19*2, CYP2C19*3 and CYP2C19*17 loci. The participants heterozygous for both ABCB1 and CYP2C19*2 and *3 loci should be defined as intermediate and poor metabolizers according to the haplotype analysis in the NUD, PUD and asymptomatic subjects. Conclusions: Consequently, fluoroquinolones/metronidazole/clarithromycin-based triple therapies can be used to eradicate H. pylori infection, if one does not know the CYP2C19 genotype of the patient.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antibakteriální látky $x terapeutické užití $7 D000900
650    _2
$a cytochrom P450 CYP2C19 $x genetika $7 D065731
650    12
$a antibiotická rezistence $7 D004352
650    _2
$a kombinovaná farmakoterapie $x metody $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a infekce vyvolané Helicobacter pylori $x farmakoterapie $x genetika $x mikrobiologie $7 D016481
650    _2
$a Helicobacter pylori $x účinky léků $7 D016480
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a polymorfismus genetický $7 D011110
650    _2
$a inhibitory protonové pumpy $x terapeutické užití $7 D054328
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Teh, Xinsheng $u Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
700    1_
$a Rajakumar, Tamayanthi $u Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
700    1_
$a Goh, Khean Lee $u Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
700    1_
$a Leow, Alex Hwong Ruey $u Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
700    1_
$a Poh, Bee Hoon $u BP Diagnostic Centre Sdn Bhd, Ipoh, Perak, Malaysia.
700    1_
$a Mariappan, Vanitha $u Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
700    1_
$a Shankar, Esaki M $u Division of Infection Biology and Medical Microbiology, Department of Life Sciences, Central University of Tamil Nadu (CUTN), Thiruvarur, India.
700    1_
$a Loke, Mun Fai $u Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. School of Life Sciences & Chemical Technology, Ngee Ann Polytechnic, Singapore, Singapore.
700    1_
$a Vadivelu, Jamuna $u Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
773    0_
$w MED00002514 $t The Journal of antimicrobial chemotherapy $x 1460-2091 $g Roč. 74, č. 1 (2019), s. 11-16
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30403784 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200522110602 $b ABA008
999    __
$a ok $b bmc $g 1525595 $s 1096793
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 74 $c 1 $d 11-16 $e 20190101 $i 1460-2091 $m Journal of antimicrobial chemotherapy $n J Antimicrob Chemother $x MED00002514
LZP    __
$a Pubmed-20200511

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...